文献速递哮喘

呼出气一氧化氮指导儿童哮喘治疗:RAACENO 3期试验

Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2022-01-31

RAACENO 是一项多中心、平行、随机对照3期试验,纳入6-15岁、过去12个月因哮喘急性发作口服激素的儿童509例,比较FeNO联合症状指导治疗与仅症状指导治疗。

要点

  • 在易急性发作儿童中,FeNO联合症状指导未减少口服激素治疗的急性发作。
  • 哮喘症状仍是指导治疗决策的唯一工具。

核心结论

  • 在易发生急性发作的哮喘儿童中,将FeNO加入症状指导治疗未减少哮喘急性发作。
  • 哮喘症状仍是指导治疗决策的唯一工具。

研究设计与样本

  • 多中心、平行、随机对照3期试验,在英国35个二级保健中心和17个初级保健招募点开展。
  • 纳入6-15岁确诊哮喘、处方吸入糖皮质激素、且入组前12个月至少一次急性发作口服激素的儿童,共509例随机。
  • 干预组为FeNO联合症状指导治疗,对照组为仅症状指导治疗,随访12个月、每3个月一次。

临床怎么用

  • 儿童哮喘治疗调整可继续以症状控制为主要依据,不宜常规加用FeNO指导治疗。
  • 对反复急性发作儿童,应强化症状评估与随访,而非依赖FeNO调整治疗。

局限性

  • 参与者和临床及研究团队未对分组设盲。
  • 17个初级保健招募点中仅7个实际招募到患者。
  • 部分评估中算法推荐未被遵循。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The benefit of fractional exhaled nitric oxide (FeNO) in guiding asthma treatment is uncertain. We evaluated the efficacy of adding FeNO to symptom-guided treatment in children with asthma versus only symptom-guided treatment. METHODS: RAACENO was a multicentre, parallel, randomised, controlled, phase 3 trial done in 35 secondary care centres and 17 primary care recruitment sites (only seven primary care sites managed to recruit patients) in the UK. Patients with a confirmed asthma diagnosis, aged 6-15 years, prescribed inhaled corticosteroids, and who received a course of oral corticosteroids for at least one asthma exacerbation during the 12 months before recruitment were included. Participants were randomly assigned to either FeNO plus symptom-guided treatment (intervention) or symptom-guided treatment alone (standard care) using a 24 h in-house, web-based randomisation system. Participants and the clinical and research teams were not masked to the group allocation. A web-based algorithm gave treatment recommendations based on the Asthma Control Test (ACT) or Childhood ACT (CACT) score; current asthma treatment; adherence to study treatment in the past 3 months; and use of FeNO (in the intervention group). Follow-up occurred at 3-month intervals for 12 months. The primary outcome was any asthma exacerbation treated with oral corticosteroids in the 12 months after randomisation, assessed in the intention-to-treat population. This study is registered with the International Standard Randomised Controlled Trial Registry, ISRCTN67875351. FINDINGS: Between June 22, 2017, and Aug 8, 2019, 535 children were assessed for eligibility, 20 were ineligible and six were excluded post-randomisation. 509 children were recruited and at baseline, the mean age of participants was 10·1 years (SD 2·6), and 308 (60·5%) were male. The median FeNO was 21 ppb (IQR 10-48), mean predicted FEV1 was 89·6% (SD 18·0), and median daily dose of inhaled corticosteroids was 400 μg budesonide equivalent (IQR 400-1000). Asthma was partly or fully controlled in 256 (50·3%) of 509 participants. The primary outcome, which was available for 506 (99%) of 509 participants, occurred in 123 (48·2%) of 255 participants in the intervention group and 129 (51·4%) of 251 in the standard care group, the intention-to-treat adjusted odds ratio (OR) was 0·88 (95% CI 0·61 to 1·27; p=0·49). The adjusted difference in the percentage of participants who received the intervention in whom the primary outcome occurred compared with those who received standard care was -3·1% (-11·9% to 5·6%). In 377 (21·3%) of 1771 assessments, the algorithm recommendation was not followed. Adverse events were reported by 27 (5·3%) of 509 participants (15 in the standard care group and 12 in the intervention group). The most common adverse event was itch after skin prick testing (reported by eight participants in each group). INTERPRETATION: We found that the addition of FeNO to symptom-guided asthma treatment did not lead to reduced exacerbations among children prone to asthma exacerbation. Asthma symptoms remain the only tool for guiding treatment decisions. FUNDING: National Institute for Health Research.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Turner, Cotton, Wood, et al. Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial. Lancet Respir Med. 2022. PMID: 35101183. doi:10.1016/S2213-2600(21)00486-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。